OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria
OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, today announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned […]